Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $23.85 USD
Change Today +4.39 / 22.56%
Volume 11.0K
HLUYY On Other Exchanges
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s-spn adr (HLUYY) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - $28.99
52 Week Low
02/9/15 - $18.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for H LUNDBECK A/S-SPN ADR (HLUYY)

Related News

No related news articles were found.

h lundbeck a/s-spn adr (HLUYY) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,811 Employees
Last Reported Date: 02/5/15
Founded in 1915

h lundbeck a/s-spn adr (HLUYY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s-spn adr (HLUYY) Key Developments

Lundbeck and Ovid Therapeutics Enters into Worldwide Licensing Agreement for Gaboxadol

H. Lundbeck A/S and Ovid Therapeutics Inc. entered into an exclusive worldwide license agreement for gaboxadol, the first oral medicine which holds the potential to treat patients with Angelman Syndrome and Fragile X Syndrome. Gaboxadol (OV101) is the only small molecule, highly selective extrasynaptic GABA(A) receptor agonist (SEGA) that has been tested in clinical trials. Under the terms of the agreement, Ovid obtained exclusive worldwide development and commercialization rights for OV101. In connection with the license, Lundbeck became a minority shareholder in Ovid, and will receive certain milestone payments and royalties on sales. Ovid is responsible for all future development and commercialization for OV101. Additional financial terms were not disclosed. Ovid plans to pursue the development of OV101 in Angelman Syndrome and Fragile X Syndrome, two orphan neurological disease indications with no available treatment options, and expects to commence a Phase 2 trial for Angelman Syndrome in 2016, followed by a Phase 2 trial in Fragile X Syndrome. The selection of Angelman Syndrome and Fragile X Syndrome as initial indications is based upon Ovid’s expectation of a highly favorable benefit-to-risk profile for OV101. The company believes that clinical and preclinical evidence to date strongly support OV101’s anti-epileptic, motor improvement and cognitive enhancement effects. OV101 is the only drug that has been shown to correct the motor deficit, a cause of major morbidity in patients, in a mouse genetic model for Angelman Syndrome. OV101 has been shown to be well tolerated in clinical trials involving approximately 3,000 patients.

H. Lundbeck A/S Approves Board Changes

H. Lundbeck A/S announced at its annual general meeting held on March 25, 2015, it approved the Lene Skole, Jesper Ovesen and Lars Holmqvist were elected to the board of directors. Christian Dyvig, Thorleif Krarup and Melanie Lee did not stand for re-election.

H. Lundbeck A/S - Shareholder/Analyst Call

Annual General Meeting


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUYY:US $23.85 USD +4.39

HLUYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €16.33 EUR -0.30
Ipsen SA €51.04 EUR -0.09
Meda AB kr125.30 SEK -4.40
Orion Oyj €28.86 EUR -0.19
Recordati SpA €17.43 EUR -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation HLUYY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S-SPN ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at